Showing results (31-40 of 204) with videos related to
Sort By:
Pageof 21
Human Gene Therapy|March 4, 2000
Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virusT Schnell, P Foley, M Wirth, et al.Methods of Information in Medicine|September 15, 2011
A generic method to monitor completeness and speed of medical documentation processesM Dugas, S Dugas-BreitJournal of Virology|November 13, 1998
A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaquesP Ten Haaft, B Verstrepen, K Uberla, et al.La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris|November 18, 1981
[Gifted children. Psychological and psychopathological aspects (author's transl)]M Dugas, M C MourenAntimicrobial Agents and Chemotherapy|October 19, 2000
Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitorsB Schmidt, K Korn, B Moschik, et al.Allergy|May 1, 1993
Manifestation of atopy is not related to patient's month of birthT Schäfer, B Przybilla, J Ring, et al.Biochemical and Biophysical Research Communications|June 26, 1995
Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitorsJ Balzarini, M Weeger, M J Camarasa, et al.European Journal of Immunology|July 1, 1992
Interleukin-4-mediated tumor suppression in nude mice involves interferon-gammaC Platzer, G Richter, K Uberla, et al.Hormone and Metabolic Research. Supplement Series|January 1, 1985
PARD: platelet aggregation as a risk factor in diabetics: results of a prospective studyH K Breddin, H J Krzywanek, P Althoff, et al.Pageof 21